Sigal Charles Elliott
Sigal Charles Elliott, DIR, reported a transaction classified as grant at Vir Biotechnology, Inc. involving 16000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 16000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- May 27, 2026
- Filing date
- May 28, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
VIR price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001628280-26-038966 Stock Option (Right to Buy)
- Transaction date
- May 27, 2026 Filed May 28, 2026, 11:25 PM · 1d delay
- Shares
- 16,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 16,000 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- F2
The RSUs will vest in full on May 27, 2027.
- F3
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F4
The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
0 other transactions
0 recent txs